DDReg pharma

DELIVER BETTER DATA TO ENSURE FASTER APPROVAL
DDReg Pharma

Regulatory

Regulatory Affairs

Knowledge Management in Regulatory Affairs (KMRA)

Knowledge Management Regulatory Affairs (KMRA) has been a recognized discipline in other sectors for over 20 years, but it has taken a long time for the biopharmaceutical business to debate and formalize it. When the ICH guideline paper Pharmaceutical Quality System: Q10 was published in 2008, it highlighted knowledge management as a major enabler of […]

Knowledge Management in Regulatory Affairs (KMRA) Read More »

Biosimilars

Identification of Medicinal Products (IDMP) – The Perspective of US FDA & EMA

IDMP is a progression of five specific guidelines established by the International Organization for Standardization (ISO) that emphasize different identification standards in the pharma industry. These standards establish an internationally recognized framework for uniquely identifying and describing pharmaceutical items, as well as for standardized documentation, coding and product information interchange across global regulators, manufacturers, suppliers

Identification of Medicinal Products (IDMP) – The Perspective of US FDA & EMA Read More »

FDA

Controlled Correspondence with FDA – An Update

The US Food and Drug Administration (FDA) has recently finalized its guidance to generic drug manufacturers on how to seek drug development information through the controlled correspondence (CC) process. This guidance finalizes the draft guidance issued in Nov 2017 and replaces the finalized guidance issued in September 2015. This update on controlled correspondence with FDA

Controlled Correspondence with FDA – An Update Read More »

Nitrosamine impurities

Nitrosamine Impurities: A Regulatory Perspective

In July 2018, the European medicines regulatory network became aware of the presence of nitrosamine impurities in an Active Pharmaceutical Ingredient (API). This was the first time that a nitrosamine impurity had been detected in a pharmaceutical drug. The unexpected delivery of these impurities resulted in voluntary product recalls on a mass scale and led

Nitrosamine Impurities: A Regulatory Perspective Read More »